Emergent BioSolutions (EBS) announced the appointment of John Fowler, Jr. to its board of directors effective March 1, 2026. Fowler brings more than three decades of leadership experience across the healthcare and financial services sectors. He will serve on the Audit and Finance Committee.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EBS:
- Emergent BioSolutions appoints Fowler to board of directors
- Emergent BioSolutions sees FY26 revenue $720M-$760M, consensus $809.4M
- Emergent BioSolutions sees Q1 revenue $135M-$155M, consensus $275M
- Emergent BioSolutions reports Q4 EPS (43c) vs. 5c last year
- Emergent BioSolutions announces up to C$140M in Canadian contracts